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Abstract
Background: The commonest cause of end-stage renal failure (ESRF) in children and young adults
is congenital malformation of the kidney and urinary tract. In this retrospective review, we examine
whether progression to ESRF can be predicted and whether treatment with angiotensin converting
enzyme inhibitors (ACEI) can delay or prevent this.
Methods: We reviewed 78 patients with asymmetric irregular kidneys as a consequence of either
primary vesico-ureteric reflux or renal dysplasia (Group 1, n = 44), or abnormal bladder function
(Group 2, n = 34). Patients (median age 24 years) had an estimated GFR (eGFR) < 60 ml/min/1.73
m2 with at least 5 years of follow up (median 143 months). 48 patients received ACEI. We explored
potential prognostic factors that affect the time to ESRF using Cox-regression analyses.
Results: At start, mean (SE) creatinine was 189 (8) µmol/l, mean eGFR 41 (1) ml/min 1.73 m2,
mean proteinuria 144 (14) mg/mmol creatinine (1.7 g/24 hrs). Of 78 patients, 36 (46%) developed
ESRF, but none of 19 with proteinuria less than 50 mg/mmol and only two of 18 patients with eGFR
above 50 ml/min did so. Renal outcome between Groups 1 and 2 appeared similar with no evidence
for a difference. A benefit in favour of treatment with ACEI was observed above an eGFR of 40 ml/
min (p = 0.024).
Conclusion: The similar outcome of the two groups supports the nephrological nature of
progressive renal failure in young men born with abnormal bladders. There is a watershed GFR of
40–50 ml/min at which ACEI treatment can be successful at improving renal outcome.
Background
Nearly half the children and young adults who develop
end-stage renal failure (ESRF) have asymmetric irregularly
shaped kidneys [1]. This appearance, often referred to as
bilateral renal scarring, is frequently associated with
vesico-ureteric reflux (VUR) and sometimes with a history
of urinary tract infection (UTI). It is generally a conse-
quence of congenital malformations of the kidneys and
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urinary tract and is variously described as ` reflux nephrop-
athy' or `chronic pyelonephritis.'
Such patients fall into two broad groups. Firstly, there is a
group who appear to have normal bladders without out-
flow obstruction and normal calibre ureters when not
micturating, described as having either primary VUR or
primary renal dysplasia. Secondly, there is a group with
some form of bladder outflow dysfunction which causes a
secondary VUR and dilated upper urinary tracts, of which
a posterior urethral valve (PUV) in males is the most com-
mon cause.
The primary group have a bimodal presentation. Com-
monly they present in childhood with UTI; the rest
present in early adult life with renal insufficiency and
often with no preceding history of UTI [2-6]. Traditionally
the diagnosis was made by recognising the characteristic
appearance of calyceal clubbing and irregular `scarring' of
the kidney on intravenous urography (IVU) [7,8]. With
significant renal insufficiency, however, these changes can
be impossible to see clearly by IVU [2], and the irregular,
asymmetrical kidney is more sensitively visualised by 99
mTc-dimercaptosuccinic acid (DMSA) renography [9,10].
In this adult population a micturating cysto-urethrogram
(MCU) frequently will not show evidence of VUR as reflux
usually ceases spontaneously in childhood [2,4,5]. In fact,
the finding of VUR is a weak predictor of renal damage in
children admitted with an UTI [11].
The appearance of proteinuria and progressive renal failure
indicates glomerular capillary hypertension (glomerular
hyperfiltration) and progressive focal and segmental
glomerulosclerosis (FSGS) [12,13]. Risk factors for
patients with reflux nephropathy developing progressive
renal failure after childhood are proteinuria, renal insuffi-
ciency, bilateral scarring of the kidneys and hypertension
[2,4,5]. Patients with congenital bladder outflow obstruc-
tion and secondary reflux, however, have usually been
excluded from such outcome studies, and very little has
been published from a nephrological perspective about
their long-term outcome.
In this retrospective observational review, from a large,
single centre nephro-urological practice, we have exam-
ined the natural history and progression to ESRF of
patients with primary and secondary reflux with asym-
metric irregular kidneys and moderate to severe renal
insufficiency. We have tested the null hypothesis of no dif-
ference in renal outcome between patients with primary
and secondary reflux.
Methods
Patients
Patients with bilaterally scarred kidneys and glomerular
filtration rate (GFR) 15–60 mls/min/1.73 m2 were identi-
fied from a review of the records of outpatients and of
patients receiving renal replacement therapy at the Renal
Unit of the Middlesex Hospital (UCL Hospitals Trust).
Most patients had been referred, as adolescents, from the
nephrology and urology clinics at the Great Ormond
Street Hospital for Children. All patients had renal scar-
ring confirmed by DMSA or 99 mTc-mercaptoacetyltrigly-
cine (MAG-3) renography, although most patients had
undergone extensive investigations.
For inclusion in this study, patients had:
• an isotopic 51Cr-edetic acid (EDTA) GFR < 60 ml/min/
1.73 m2; or estimated GFR < 60 ml/min/1.73 m2
• apparently stopped growing and with a steady body
weight (so that plasma creatinine could be used to esti-
mate serial GFRs), and
• data for at least 5 years of follow up.
Patients specifically excluded from this study were those
with bladder exstrophy, neuropathic bladders, or any
form of urinary diversion (conduit or reservoir). In our
analysis, the patients were divided into two broad groups:
Group 1: those with normal calibre ureters and normal
bladders (Primary group)
Group 2: those with megaureters, hydronephrosis and
abnormal bladders (Secondary group).
Data
Glomerular filtration rate (GFR) was estimated by single
exponential analysis of the plasma clearance of 51Cr-
edetic acid (EDTA) following a single intravenous injec-
tion with blood samples taken after 2 and 4 hours [14].
Plasma (PCr) and urine creatinine concentration were
measured by the Jaffe technique using an autoanalyser
(Chemlab Instruments, Hornchurch, UK) and urinary
protein (Uprot) by turbidometric assay following precipi-
tation with trichloroacetic acid.
GFR was estimated by different formulae and compared
with the isotopic GFR. The Jelliffe formulae (I and II)
[15,16] have been shown to approximate most closely
low values of GFR when compared with the inulin clear-
ance [17].
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Jelliffe I (ml/min/1.73 m2) [15]:- "(100 × 88/ PCr µmol/
l) - 12" for males; and "(80 × 88/creatinine µmol/l) - 7"
for females.
Jelliffe II (ml/min/1.73 m2) [16]:- "(98–0.8(age-20)) ×
88/ PCr µmol/l" for males. (Jelliffe II × 0.9 for females).
[The original formulae used creatinine mg/dl. Conversion
to µmol/l introduces the factor 88].
We found that a mean of these 2 formulae gave closer
approximations to measured isotopic GFR than the other
methods. We have termed this mean value `estimated
GFR' (eGFR). All measured values of 51Cr EDTA GFRs
were compared with the eGFR calculated using the con-
temporary value of plasma creatinine. 151 values of cor-
rected isotopic GFR (ml/min/1.73 m2) from a range of
12–60 ml/min/1.73 m2 were found to have no significant
bias (-0.34 ml/min/1.73 m2 with a 95% CI of -1.19 to
0.51 ml/min/ 1.73 m2) and an agreement within limits of
-11.0 to 10.3 ml/min/1.73 m2.
Normal bladder: patients presenting after adolescence were
considered to have a normal bladder if they had no blad-
der outflow symptoms, a normal urine flow rate (> 15 ml/
sec) and no residual urine volume seen by ultrasound
after voiding.
Declining renal function: the rate of progression of CRF, -
delta GFR (`-∆GFR'), was calculated as the rate of change
of eGFR and is shown as ml/min/year.
Proteinuria: was initially measured as the amount of pro-
tein (g) in a 24-hour urine collection. Since 1995 pro-
teinuria was more commonly measured on a random
(spot) sample of urine at clinic visits with the proteinuria
expressed as mg protein/mmol creatinine (normal labora-
tory range 0–13 mg/mmol). As all 24 hour urine data
(Uprot) included creatinine excretion (mmol/24 hours)
we have been able to calculate protein/creatinine ratios
(Up/Cr). Using the data from 161 separate 24-hour collec-
tions, we assessed how proteinuria in g/day predicts pro-
tein/creatinine ratios. Paired values ranged from 0.1–8.6
g/day and 8–700 mg protein/mmol creatinine, with a
high correlation (r = 0.90). The regression equation was
[Up/Cr = 90.3 × Uprot0.94].
Hypertension was defined as either blood pressure consist-
ently > 140/85 mmHg, or patients receiving blood pres-
sure lowering therapy.
End-stage renal failure (ESRF): was taken to be the date
when the patient began dialysis. To calculate changes in
renal function with time the eGFR was assumed to be 8
ml/min at this time.
Outcome: Renal outcome was defined as having reached
ESRF or not at last review.
ACEI therapy
Since June 1986 some patients were started on ACEI ther-
apy when anti-hypertensive therapy was required. In addi-
tion, some anti-hypertensive regimens were changed to
ACEI therapy. A small group with blood pressure <140/85
were started on ACEI therapy because of increasing pro-
teinuria. Some patients never received ACEI because ESRF
was reached before the use of ACEIs in renal insufficiency
had become routine.
Patients, who were started on ACEI for hypertension, were
advised to restrict their salt intake and the initial aim was
for a blood pressure of ≤ 130/70. If ACEI alone did not
lower the blood pressure to the target a diuretic was
added. The latter was not always possible in Group 2
patients who might already have features of hypovolae-
mia secondary to their renal tubular pathology. No
patient ever received any immunosuppressive drug.
Data collection
Only data from the start and end of the study are pre-
sented from all 78 patients. Of the 48 patients who were
treated with ACEI, we also report data on 28 of the
patients (for whom it was available for at least 18 months
before and 48 months after the introduction of ACEI.) at
the start of ACEI therapy and again at 2 years after start of
therapy.
`Statistical Analysis'
Means were compared within groups by paired samples t-
test, and between groups by Wilcoxon rank-sum test. The
time scale was time since birth, since the setting was of a
congenital disease eventually leading to renal failure. It
was checked graphically that there was no obvious pattern
to loss to follow up over time. Renal outcome (reaching
ESRF or not) was compared between groups using Kaplan-
Meier survival plots. Outcomes were quantified as the
median survival outcome in months (with 95% Confi-
dence Intervals [CI]). This is equivalent to the median
time for 50% of the group to reach ESRF. Differences in
renal outcome over time were tested using log-rank tests.
For graphical examination of the proportionality, contin-
uous variables were grouped into approximate tertiles.
The Cox proportional hazards model was chosen for fur-
ther analysis. Continuous variables were centred on the
mean. Protein/urine creatinine ratios were log-trans-
formed for further analyses. Treatment with ACEI was
entered as a time-changing variable to take account of the
variable start of treatment after referral. Univariable
regression models estimated crude (unadjusted) effects of
the prognostic variables. Since it is possible that the effect
ACEI depends on the GFR at start of treatment (entered as
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continuous variable), especially in patients with moderate
to severe renal insufficiency, an interaction between those
variables was fitted. Variables were entered in the
multivariable model in a stepwise forward fashion. Anal-
yses were performed using SPSS for Windows v10.1. and
Stata 8 (Stata Corporation, Texas, USA).
Results
Demography
Data from 78 patients, who were first seen between
December 1969 and February 1988, were analysed.
Demographic details are presented in Table 1. The age of
patients at the start of the study period ranged from 15–
49 years (median 23 years) with one lady aged 65 years.
Group 1 (n = 44; 50% female) were patients who had pri-
mary VUR or primary renal dysplasia. Twenty two patients
(71% female) presented in childhood with a UTI. In each
case, MCU performed at a median age of 7 years showed
reflux which was either bilateral (82%) or unilateral
(18%). In contrast, the remainder (n = 22) presented at a
median age of 24 years. Only 32% were female and they
almost invariably presented either with hypertension after
starting a contraceptive pill or with complications during
pregnancy. Only 2 had had a MCU performed and neither
showed VUR.
Group 2 patients (n = 34; 6% female) had the following
diagnoses: PUV (n = 15), prune belly syndrome (n = 2),
single dysplastic kidney with megaureter (n = 2), renal
dysplasia with abnormal bladder function (n = 2), bilat-
eral megaureters (n = 1), megacystis and megaureters (n =
4), and finally a group (n = 8) in whom the initial diagno-
sis (pre-1979) had included "bladder neck obstruction".
Six of these had megacystis and megaureters and might
now be termed `pseudo-prune belly syndrome'.
Renal outcome
By Group: The median survival time of Group 1 versus
Group 2 was compared by log rank test: 231 months
(95% CI: 153–309) vs. 162 months (95% CI: 135–189)
respectively, p = 0.35. There was no evidence for a major
difference in renal outcome between these patients with
primary and secondary reflux. Thus for subsequent analy-
ses the data from all 78 patients was combined.
By eGFR: We compared renal outcome for all patients after
they were stratified by initial eGFR into four groups (15–
30, 31–40, 41–50, and 51–60 ml/min/1.73 m2) (see Fig
1). Of 18 patients with eGFRs >50 ml/min, only 2 (11%)
reached ESRF: however, eGFR still declined in the other 16
by 1.30 ml/min/yr and mean proteinuria rose from 35 to
55 mg/mmol creatinine, despite 12 patients (75%) receiv-
ing ACEI.
By Proteinuria: We compared renal outcome for all
patients after they were stratified by initial proteinuria
into three groups (0–99, 100–199, and ≥ 200 mg/mmol)
(Fig 2). The great significance of proteinuria is empha-
sised further by the observation that seven patients with
proteinuria ≥ 200 mg/mmol reached ESRF despite initial
eGFRs ≥ 40 ml/min. In contrast, none of 19 patients with
proteinuria <50 mg/mmol creatinine at start developed
ESRF after a median follow up of 160 months (range 87–
227).
Proteinuria increased with time and declining function in
both Groups (Table 2) but levels were consistently higher
in Group 2 compared with Group 1 patients (Table 1).
Table 1: Demographic Details At Entry (n = 78). Data shown are means (SE); Dates (month/year) are medians. Because isotopic GFRs 
were not always performed this data is not shown in Table, but 26 Group 1 patients had a mean (SE) isotopic-GFR of 41.2 (2.1) ml/min/
1.73 m2 with a contemporaneous mean eGFR of 44.2 (2.3) ml/min/1.73 m2, and the 26 Group 2 patients with an isotopic GFR of 40.2 
(2.3) had an eGFR 41.5 (2.0) ml/min 1.73 m2.
Group 1 (Primary reflux) Group 2 (Secondary reflux) TOTAL
Total 44 34 78
Male:Female 22:22 32:2 54:24
Date at start (median) 8/1988 6/1986 2/1987
Age (year) 28.9 (1.6) 22.2 (1.4) 26 (1.1)
Creatinine (µmol/l) 178 (9.0) 203 (13) 189 (7.7)
eGFR (ml/min) 42.3 (1.8) 40.3 (2.1) 41.4 (1.3)
Proteinuria (g/d) 1.63 (0.19) 1.83 (0.33) 1.72 (0.2)
Protein/creatinine (mg /mmol) 136 (14) 154 (27) 144 (14)
Hypertension 18 (41%) 5 (15%) 23 (29%)
Treatment with ACEI 32 (73%) 16 (47%) 48 (62%)
Treatment date (median) 4/1992 8/1993 11/1992
Total months of follow up 145 (11) 143 (9) 144 (7)
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There was a strong correlation between rate of loss of func-
tion and proteinuria at start (R = 0.63, p < 0.0001), and
end of study: (R = 0.69).
ACEI treatment
48 patients commenced ACEI therapy at a median of 48
months (range 0–311) after the start of the study, by
which time their median eGFR had fallen from 46 (range
15–60) to 36 (10–60) ml/min/1.73 m2.
Effect on renal outcome
Table 3 shows the results of both the univariable and mul-
tivariable analyses. For every variable entered into the
model the assumption of proportionality of hazards was
met. It was notable, given the small number of patients of
our sample, that we were able to detect an interaction
between treatment with ACEI and renal function at treat-
ment start. The effect of ACEI was estimated to have its
main effects just above a GFR of 40 ml/min. In the crude,
as well as in the full model, neither sex nor type of reflux
seem to have a significant effect upon time to ESRF since
referral. At entry to study, both the amount of proteinuria
and eGFR were important prognostic variable towards
ESRF in crude as well as adjusted analyses. There was one
65 year old lady. Refitting the final model omitting this
record did not affect the estimates.
Renal outcome stratified for eGFR (ml/min/1.73 m2) at startFigure 1
Renal outcome stratified for eGFR (ml/min/1.73 m2) at start. eGFR 51–60 vs 41–50: p = 0.17; eGFR 41–50 vs 31–40: 
p = 0.004; eGFR 31–40 vs 15–30: p = 0.041.
Renal outcome stratified
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Renal outcome stratified for proteinuria (mg/mmol) at startFigure 2
Renal outcome stratified for proteinuria (mg/mmol) at start. 10 – 99 vs 100–199 mg/mmol: p = 0.009; 100–199 vs 
>200 mg/mmol: p = 0.002.
Table 2: Creatinine, eGFR, proteinuria and ACE-I stratified by renal function at outset. Data are medians (range). Proteinuria*: b) vs c) 
p = 0.06, c) vs d) p = 0.031; -∆ eGFR†: b) vs c) p= 0.14, c) vs d) p = 0.012; Total -∆GFR is the rate of change of function in ml/min/yr from 
start to last follow up; Rx ACEI is the percentage of patients receiving ACEI treatment
Renal Function groups N= Creatinine eGFR Proteinuria -∆ eGFR Total -∆ eGFR post-ACEI Rx ACEI
µmol/l ml/min/1.73 m2 mg/mmol ml/min/yr ml/min/yr
a) 15–30 ml/min 16 295 (220–450) 24 209 (57–680) 2.94 (0.55–5.7) 2.63 (1.51–4.3) 38%
b) 31–40 ml/min 14 198 (160–233) 36 200 (71–275)* 3.05 (0.95–7.4) 1.7 (0.9–3.45) 50%
c) 41–50 ml/min 30 160 (130–185) 46 100 (10–276)* 1.71 (0.44–8.21)† 1.68 (0.66–7.85) 77%
d) 51–60 ml/min 18 130 (115–153) 55 38* (10–250) 1.34 (0.24–3.41)† 1.76 (0.24–3.73) 72%
Renal outcome stratified
for Proteinuria at start
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Effect on rate of progression and proteinuria
We examined the effect of ACEI on 28 patients with dete-
riorating function for whom data was available for at least
18 months before and 48 months after the introduction of
ACEI. ACEI reduced the rate of loss of renal function dur-
ing the first 24 month period of follow-up, but the benefit
was greater in the subsequent follow-up period with the
rate slowing from a median of -1.86 before ACEI to -1.48
ml/min/yr (p = 0.007). ACEI treatment was associated
with a reduction in proteinuria after 24 months of ther-
apy. However, proteinuria had increased at last follow up
owing to loss of the anti-proteinuric effect in half the
group (Fig 3).
Analysis of 30 patients who did not receive an ACEI pro-
vides indirect support of benefit from this treatment. The
median rate of loss of renal function for 25 of these
patients who started with a eGFR ≤ 50 ml/min was 2.80
ml/min/yr and if initial proteinuria was ≥ 50 mg/mmol,
(n = 23) the rate of loss of renal function was 3.0 ml/min/
yr.
Blood pressure
At the start of the study 18 (41%) Group 1 patients and 5
(15%) Group 2 patients were hypertensive. Group 2
patients tended to be normotensive and some were started
on an ACEI for proteinuria. At ESRF or last follow up, all
patients were on conventional anti-hypertensive therapy
or ACEI, except for two Group 2 patients.
Discussion
There is a consensus that patients with renal insufficiency
and proteinuria have progressive renal failure, that the rate
of decline of function is proportional to the magnitude of
the proteinuria, and that angiotensin antagonists both
slow the rate of progression and reduce proteinuria [18-
20]. Our data show that this nephro-urological group of
patients is no exception.
While VUR patients with abnormal bladders almost invar-
iably present in early childhood, patients with normal
bladder function have a bimodal presentation. In one
series from New Zealand, 42 patients (36 adults) had
ESRF with reflux nephropathy. Many had presented with
advanced renal insufficiency, hypertension, and proteinu-
ria, and only 22% of males and 58% of females had a his-
tory of UTI. Similarly, in our study, VUR had been proven
in 50% of patients with primary reflux nephropathy and
these patients (71% female) had almost invariably pre-
sented with an UTI in childhood (median age 7.0 years).
In contrast, the other half (32% female) presented at a
median age of 24 years with advanced disease and persist-
ent reflux was not demonstrated in the 2 patients who
underwent a MCU. Similar to the New Zealand experience
[5,21,22], nearly all our women presented with hyperten-
sion after starting a contraceptive pill or with complica-
tions during pregnancy, whereas the men were found to
have proteinuria, hypertension or renal insufficiency –
usually on routine investigation.
Although reflux nephropathy is frequently viewed as a dis-
ease of little girls with recurrent UTIs [7], our data
confirms findings of others regarding the late presentation
of adults with asymmetric irregular kidneys. In a UK series
from Newcastle, only 9% presented under 20 years of age
[2], in Australia 22% under 15 years [4], and from Italy
10% under 12 years [6]. Furthermore it is clear from pub-
Table 3: Estimated crude and adjusted hazard ratios for incidence of ESRF in all patients. *full model includes all variables, since analyses 
were conducted on the age-scale, effects are taking account of current age; **interaction parameters (95%CI): crude model: -0.088 (-
0.162,-0.014); p = 0.019 full model: -0.093 (-0.174,-0.012); p = 0.024; #effect of 100 mg/mmol creatinine = (displayed hazard ratio)0.7 effect 
of 200 mg/mmol creatinine = (displayed hazard ratio)1.4; ##effect of 10 ml/min/1.73 m2 decrease = (displayed hazard ratio)2 effect of 15 
ml/min/1.73 m2 decrease = (displayed hazard ratio)3
Hazard ratios
Estimated effects of categories/unit crude 95%CI p-value Adjusted* 95%CI p-value
Gender female 1.00 1.00
male 1.17 (0.55, 2.50) 0.677 0.55 (0.21,1.39) 0.205
Type of reflux primary 1.00 1.00
secondary 1.28 (0.65, 2.55) 0.478 1.73 (0.73, 4.06) 0.211
Proteinuria per 50 mg/mmol proteinuria increase# 1.71 (1.33, 2.20) <0.001 1.50 (1.17, 1.91) 0.001
eGFR** per 5 ml/min/1.73 m2 decrease## 1.38 (1.16, 1.64) <0.001 1.29 (1.05, 1.58) 0.016
ACE inhibitor** at 30 ml/min/1.73 m2 0.53 (0.22, 1.29) 0.162 0.67 (0.27, 1.67) 0.393
at 35 ml/min/1.73 m2 0.34 (0.12, 1.00) 0.051 0.42 (0.14, 1.26) 0.121
at 40 ml/min/1.73 m2 0.22 (0.06, 0.84) 0.027 0.27 (0.07, 1.04) 0.058
at 45 ml/min/1.73 m2 0.14 (0.03, 0.73) 0.02 0.17 (0.03, 0.91) 0.039
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lished reviews [2,4-6] and dialysis programmes [5,23],
that there is no female preponderance at ESRF.
In 1978 Kincaid-Smith and her colleagues [12] reported
that progressive renal failure with primary VUR was very
unlikely unless proteinuria was in excess of 1.0 g/day
(equivalent to 100 mg protein/mmol creatinine). In a
subsequent report, in which 147 such patients were
followed for a mean of 6.9 years, renal function deterio-
rated in 37% and 14% progressed to ESRF. Proteinuria,
elevated creatinine and hypertension at presentation were
associated with relative risks (RR) of 25, 24 and 4.5
respectively for the development of progressive renal fail-
ure [4].
In an Italian study [6], 80 patients were followed for a
mean of 5.6 years and retrospectively stratified into those
with stable renal function and those with slowly or rap-
idly progressive renal failure. For those with progressive
nephropathy, there was no difference in initial renal func-
tion but proteinuria was much greater in the rapidly pro-
gressive group. Loss of function was unusual with
creatinine ≤ 1.7 mg/dl (150 µmol/l) and inevitable above
that concentration [6].
In a UK study from Newcastle, proteinuria and renal
insufficiency (plasma creatinine >130 µmol/l) were
present from presentation in 21% and 13% of 125
patients respectively, and with time (mean 5.9 years) a
further 21% developed proteinuria and 22% renal insuffi-
ciency. In all the 16 patients with progressive renal failure,
the decline was linear. In a subsequent report, progressive
renal failure did not develop in 138 adult patients with
normal function at the start (plasma creatinine < 90
µmol/l) [3].
Our data support the established relationship between the
risk of progressive nephropathy and renal insufficiency
Effect of ACEI on ProteinuriaFigure 3
Effect of ACEI on Proteinuria. Time points are 1) start of study, 2) at begin of ACEI therapy, 3) 2 years after begin ACEI; 
4) at end of study. Proteinuria* at ACEI vs +2 years post-ACEI; p < 0.0001.
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with proteinuria, but suggests a watershed range for renal
function as a predictor of outcome. When the eGFR
exceeds 40–50 ml/min/1.73 m2 nephropathy rarely
progresses, but disease progression is invariable when
function is worse. Nakashima et al. similarly reported that
an isotopic GFR less than 49 ml/min predicted decline to
ESRF [24].
The other determining factor of poor renal outcome is
proteinuria, and we find that deterioration can be
expected when proteinuria exceeds 50 mg/mmol (0.5 g/
d). In a Japanese study, serial biopsy samples from
patients with reflux nephropathy confirmed the close
association between the degree of renal scarring, the
extent of the glomerular pathology, and proteinuria
[25,26]. Once extensive glomerular sclerosis was present
there was conspicuous glomerular hypertrophy which
correlated with increasing proteinuria. This is consistent
with our findings that proteinuria increased as renal func-
tion declined. The prognostic importance of proteinuria is
emphasised by our observation that 6 of the 25 (24%)
patients with proteinuria ≥ 200 mg/mmol developed
ESRF despite initial eGFRs exceeding 40 ml/min. On the
other hand, the survival outcome benefit of ACEI
treatment was most conspicuous when patients with pro-
teinuria = 100 mg/mmol were compared (p < 0.00001).
In a 10-year follow up study of 52 children, randomised
to medical or surgical management of severe bilateral
VUR (grades III-IV) between 1985–1989, progressive
renal failure developed in only 4 children (2 from each
group) all of whom had GFRs at or below 40 ml/min/1.73
m2 at outset [27].
Despite the few long-term studies of adult patients with
primary VUR and reflux nephropathy [2-5], there is
almost no renal outcome data on adult patients born with
abnormal bladder function (Group 2) [28]. It had been
our clinical impression that those with secondary reflux
did less well, but although there was a trend for Group 2
patients to do less well this was not statistically significant,
although a difference might emerge if large numbers were
studied.
Progressive renal damage due to congenital outflow tract
obstruction may be averted by urological intervention.
This is not, however, always successful and even treatment
in utero may not prevent progressive renal damage [29]
and the development of ESRF. Despite correction of ure-
thral obstruction, 30% of boys with PUV develop ESRF by
the age of 15 years and this may be due to continuing
bladder dysfunction [28]. Most boys born with abnormal
bladders who develop ESRF have posterior urethral valves,
but in our series 35% had presented with megacystis/meg-
aureters. Before 1975, this was attributed to bladder neck
obstruction and treated by bladder neck surgery but sub-
sequently it has been determined that most of this group
are born with gross bilateral VUR. The dilated bladders
and ureters are attributed to the constant recycling of
refluxed urine, sometimes exacerbated by the nephro-
genic polyuria [30] although urodynamic studies often
show high voiding pressure suggestive of detrusor/sphinc-
ter dyssynergia. The concept that progressive renal failure
is often `nephrogenic' in origin, rather than urological, is
supported by our data which show that adults with abnor-
mal bladders do not behave significantly differently to
those with primary reflux – although the numbers are rel-
atively small. Nevertheless, if renal function deteriorates
in a urological patient in the absence of proteinuria, then
some other cause (such as obstruction) must be sought.
Apart from small numbers, the limitations of this study
are the usual ones in observational research with effect
estimates that are potentially confounded. We believe,
however, that it would not now be possible to design a
prospective study in which ACEI therapy was with held
from one group. In this study, ACEI therapy improved
renal outcome although non-ACEI patients were generally
from an earlier period and not necessarily seen in a
specialist clinic. The analysis demonstrated a long-term
benefit for ACEI both in slowing the rate of loss of func-
tion and in reducing proteinuria. However, ACEI therapy
appeared to be ineffective if started when the eGFR was
already = 30 ml/min.
We have studied a group of patients whose renal pathol-
ogy is not immunological and whose residual functioning
tissue is not homogenously distributed. The pathophysi-
ology is similar to experimental sub-total nephrectomy
which results in proteinuria, progressive glomerulosclero-
sis and renal failure [13,31]. Like the experimental mod-
els, we have found that there is a watershed level of GFR
above which ESRF is unlikely and below which it is invar-
iable, and that the most important harbinger of poor out-
come is proteinuria. Why, however, one patient with a
GFR of 45 ml/min should have no proteinuria and do
well, while another with a GFR of 50 and 2 g/day of pro-
teinuria does badly, remains to be determined. Long term
studies [27] and follow up observations on outcome [23]
in patients with reflux nephropathy confirm no benefit
from anti-reflux surgery. This is consistent with our cur-
rent view that progressive nephropathy is nephrogenic
rather than urological in origin.
Conclusions
Patients with a GFR of <60 ml/min need careful follow up
and we would recommend that anyone with increasing
proteinuria, or proteinuria >50 mg/mmol (0.5 g/d) is
started on an angiotensin antagonist to reduce proteinuria
and slow the rate of progression of the renal failure.
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